Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors (Q34616576)

3 August 2017

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors (English)

1 reference

3 August 2017

1 reference

Jens Rüter

1

1 reference

3 August 2017

Scott J Antonia

2

1 reference

3 August 2017

Howard A Burris

3

1 reference

3 August 2017

Richard D Huhn

4

1 reference

3 August 2017

Robert H Vonderheide

5

1 reference

3 August 2017

15 November 2010

1 reference

Cancer Biology and Therapy

3 August 2017

1 reference

3 August 2017

10

1 reference

3 August 2017

10

1 reference

3 August 2017

983-993

1 reference

Effector and regulatory B cells: modulators of CD4+ T cell immunity

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

Cytotoxic T-lymphocyte-associated antigen-4.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

Prospect of targeting the CD40 pathway for cancer therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

The CD40 antigen and its ligand

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047092

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

7 July 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.10.13251

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.10.13251

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.10.13251

The TRAIL to selective tumor death

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.10.13251

Immunology. Licence to kill.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.10.13251

Agonistic anti-CD40 antibody profoundly suppresses the immune response to infection with lymphocytic choriomeningitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.10.13251

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.10.13251

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

21 January 2018

1 reference

12 December 2020

Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma

1 reference

12 December 2020

An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model

1 reference

12 December 2020

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

1 reference

12 December 2020

Identifiers

DOI

10.4161/CBT.10.10.13251

1 reference

3 August 2017

1 reference

3 August 2017

1 reference